Colossal Biosciences
An American biotechnology company focused on de-extinction research. The company uses gene-editing tools to revive extinct species, including the woolly mammoth, dire wolf, and dodo bird, while also developing technologies for the conservation of existing endangered species.
Timeline (last 90 days)
Biotech company Colossal Biosciences announced last week the launch of a brand-new AI platform aimed at accelerating its de-extinction research process, helping research teams more efficiently analyze genetic data, simulate species reconstruction pathways and optimize experimental workflows.
Colossal Biosciences was founded by Ben Lamm and George Church, with the core goal of using CRISPR gene editing, stem cell technology and synthetic biology methods to bring extinct species back to Earth.
Colossal Biosciences' previously publicly announced flagship projects include the woolly mammoth, the thylacine (Tasmanian tiger) and the dodo.
Colossal is developing artificial womb technology to enable the simultaneous gestation of hundreds of mammoths without occupying the 22-month gestation period of Asian elephants.
Beth Shapiro is the Chief Science Officer of Colossal Biosciences, an evolutionary biologist, and a former Howard Hughes Medical Institute investigator.
Northern Australian quolls die from the toxic invasive species cane toad, and Colossal's Australian partners have enabled quolls to eat cane toads without dying by changing a single base in a single gene.
Colossal announced the results of cloning red wolves, introducing new genetic diversity into the existing red wolf population by cloning coyote-like animals carrying more than 75% red wolf ancestry.
The dire wolf project reconstructs the dire wolf by extracting and sequencing the genome from dire wolf fossils, identifying the genetic changes that made dire wolves larger, stronger, and lighter in coat color, and engineering those changes into the gray wolf genome.
The dire wolf reconstruction project involved a total of 20 selected gene edits.
All Facts (9)
Colossal Biosciences' previously publicly announced flagship projects include the woolly mammoth, the thylacine (Tasmanian tiger) and the dodo.
50%UnverifiedColossal Biosciences was founded by Ben Lamm and George Church, with the core goal of using CRISPR gene editing, stem cell technology and synthetic biology methods to bring extinct species back to Earth.
50%UnverifiedThe dire wolf reconstruction project involved a total of 20 selected gene edits.
50%UnverifiedColossal is developing artificial womb technology to enable the simultaneous gestation of hundreds of mammoths without occupying the 22-month gestation period of Asian elephants.
50%UnverifiedBeth Shapiro is the Chief Science Officer of Colossal Biosciences, an evolutionary biologist, and a former Howard Hughes Medical Institute investigator.
50%UnverifiedNorthern Australian quolls die from the toxic invasive species cane toad, and Colossal's Australian partners have enabled quolls to eat cane toads without dying by changing a single base in a single gene.
50%UnverifiedColossal announced the results of cloning red wolves, introducing new genetic diversity into the existing red wolf population by cloning coyote-like animals carrying more than 75% red wolf ancestry.
50%UnverifiedThe dire wolf project reconstructs the dire wolf by extracting and sequencing the genome from dire wolf fossils, identifying the genetic changes that made dire wolves larger, stronger, and lighter in coat color, and engineering those changes into the gray wolf genome.
50%UnverifiedBiotech company Colossal Biosciences announced last week the launch of a brand-new AI platform aimed at accelerating its de-extinction research process, helping research teams more efficiently analyze genetic data, simulate species reconstruction pathways and optimize experimental workflows.
50%